In a landmark decision, India's Supreme Court rejects Novartis' (NVS) bid for patent protection...

|About: Novartis AG (NVS)|By:, SA News Editor

In a landmark decision, India's Supreme Court rejects Novartis' (NVS) bid for patent protection for its cancer drug Glivec, thus allowing the country's generic drugmakers to continue to sell copies at a lower price. Novartis India fell 1.8% on the Bombay exchange while generic manufacturer Natco Pharma surged 5.4%.